Janus Henderson Group PLC lessened its stake in shares of Novartis AG (NYSE:NVS - Free Report) by 0.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,541,861 shares of the company's stock after selling 7,052 shares during the period. Janus Henderson Group PLC owned about 0.12% of Novartis worth $292,365,000 at the end of the most recent quarter.
A number of other large investors also recently bought and sold shares of the business. Founders Financial Securities LLC raised its stake in Novartis by 3.4% in the second quarter. Founders Financial Securities LLC now owns 2,832 shares of the company's stock worth $301,000 after buying an additional 94 shares in the last quarter. Steigerwald Gordon & Koch Inc. raised its stake in Novartis by 4.8% in the third quarter. Steigerwald Gordon & Koch Inc. now owns 2,091 shares of the company's stock worth $241,000 after buying an additional 95 shares in the last quarter. NBC Securities Inc. raised its stake in Novartis by 0.9% in the second quarter. NBC Securities Inc. now owns 10,492 shares of the company's stock worth $1,116,000 after buying an additional 97 shares in the last quarter. Centaurus Financial Inc. grew its holdings in Novartis by 1.7% in the third quarter. Centaurus Financial Inc. now owns 5,728 shares of the company's stock worth $659,000 after purchasing an additional 98 shares during the last quarter. Finally, Portside Wealth Group LLC grew its holdings in Novartis by 3.4% in the second quarter. Portside Wealth Group LLC now owns 3,000 shares of the company's stock worth $319,000 after purchasing an additional 99 shares during the last quarter. Institutional investors own 13.12% of the company's stock.
Novartis Trading Down 2.6 %
Shares of NYSE:NVS traded down $2.73 during mid-day trading on Wednesday, reaching $101.83. 1,621,076 shares of the company were exchanged, compared to its average volume of 1,336,001. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.11 and a quick ratio of 0.90. The firm has a market cap of $208.14 billion, a price-to-earnings ratio of 11.83, a P/E/G ratio of 1.51 and a beta of 0.56. The firm's 50-day simple moving average is $109.95 and its 200 day simple moving average is $110.25. Novartis AG has a 1 year low of $92.35 and a 1 year high of $120.92.
Novartis (NYSE:NVS - Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $2.06 earnings per share for the quarter, beating analysts' consensus estimates of $1.94 by $0.12. Novartis had a net margin of 35.96% and a return on equity of 34.80%. The business had revenue of $12.82 billion for the quarter, compared to analyst estimates of $12.62 billion. During the same period last year, the business earned $1.74 EPS. Equities research analysts forecast that Novartis AG will post 7.66 EPS for the current year.
Analyst Ratings Changes
Several equities analysts have issued reports on NVS shares. Erste Group Bank reaffirmed a "hold" rating on shares of Novartis in a report on Tuesday, November 19th. BMO Capital Markets boosted their price objective on shares of Novartis from $118.00 to $120.00 and gave the company a "market perform" rating in a report on Wednesday, October 30th. The Goldman Sachs Group reissued a "neutral" rating and set a $121.00 price objective (up from $119.00) on shares of Novartis in a report on Thursday, September 5th. Bank of America lowered shares of Novartis from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $135.00 to $130.00 in a report on Wednesday, September 11th. Finally, HSBC downgraded shares of Novartis from a "hold" rating to a "reduce" rating in a research report on Wednesday. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $121.50.
Check Out Our Latest Stock Analysis on NVS
Novartis Profile
(
Free Report)
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Featured Stories
Before you consider Novartis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.
While Novartis currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
